Headline News

 

FDA clears Jaypirca as first line treatment for certain previously untreated CLL and SLL patients

Posted on October 05, 2026

AstraZeneca finalises $2 billion stake in Summit Therapeutics to speed up ivonescimab combination research

Posted on October 05, 2026

AstraZeneca opens $1 billion global research centre in Cambridge Massachusetts that will lift its local workforce by more than 50 per cent

Posted on October 05, 2026

Sanofi and Regeneron bring four new long acting antibodies into Dupixent partnership in deal worth up to $8 billion

Posted on October 05, 2026

Wegovy reduces liver fat to normal levels in most adults with obesity in STEP UP analysis

Posted on October 05, 2026

Abbott launches SimpleScreen CRC blood test for colorectal cancer screening

Posted on October 05, 2026

Zasocitinib outperforms deucravacitinib in Phase III psoriasis study

Posted on October 04, 2026

Zumilokibart meets primary endpoint in Phase II atopic dermatitis study

Posted on October 04, 2026

ABBV 295 shows extended half life and weight loss in Phase I obesity study

Posted on October 04, 2026

RINVOQ shows continued repigmentation through 76 weeks in nonsegmental vitiligo

Posted on October 04, 2026

IMAAVY maintains disease control through two years in adolescents with generalised myasthenia gravis

Posted on October 04, 2026

ICOTYDE maintains skin clearance through two years in difficult to treat plaque psoriasis

Posted on October 04, 2026

FDA expands CAMZYOS approval to paediatric patients with obstructive hypertrophic cardiomyopathy

Posted on October 04, 2026

Foundayo linked to lower predicted long term diabetes and cardiovascular risk in ATTAIN 1 analysis

Posted on October 04, 2026

FDA expands Jaypirca approval to certain previously untreated CLL and SLL patients

Posted on October 04, 2026